Research goal
Fertility & Reproductive Health
Covers compounds researched for their roles in reproductive hormone regulation, ovulation induction, gonadotropin stimulation, and HPG axis support in male and female fertility research.
Relevant Compounds
| Compound | Class | Primary mechanism | Commonly reported for | Link |
|---|---|---|---|---|
| Kisspeptin | KISS1 neuropeptide | Hypothalamic GnRH pulse driver; triggers LH/FSH surge; ovulation trigger in IVF | Ovulation induction, LH surge, male fertility research | View profile → |
| PT-141 | Melanocortin agonist (MC3R/MC4R) | CNS arousal and sexual motivation; indirect HPG axis interaction | Libido and arousal in fertility context | View profile → |
Research Context
The HPG axis — hypothalamus → pituitary → gonads — is the primary hormonal cascade governing reproductive function in both sexes. In women, pulsatile GnRH drives LH and FSH release, which orchestrate follicular development, oestrogen production, and the pre-ovulatory LH surge that triggers ovulation; the luteal phase then depends on progesterone from the corpus luteum. In men, the same upstream signalling drives Leydig cell testosterone synthesis and Sertoli cell support of spermatogenesis. Disruption at any level of this axis — whether hypothalamic (insufficient GnRH), pituitary (inadequate gonadotropin output), or gonadal (primary failure) — impairs fertility. Kisspeptin's position as the upstream driver of GnRH pulsatility makes it relevant to conditions involving hypothalamic dysfunction.
Kisspeptin's most established clinical application in reproductive medicine is as an IVF ovulation trigger. In conventional IVF stimulation, a human chorionic gonadotropin (hCG) injection is used to trigger the LH surge that matures follicles for retrieval. hCG's long half-life and persistent LH-like activity carries a risk of ovarian hyperstimulation syndrome (OHSS) — a potentially serious complication involving fluid accumulation, pain, and in severe cases, thrombosis. Kisspeptin-10 (K-10) has been investigated as a physiologically endogenous alternative trigger: administered IV, it stimulates an endogenous LH surge rather than providing exogenous hCG activity, with the surge self-terminating as the kisspeptin clears. Clinical trials at Imperial College London demonstrated equivalent oocyte retrieval rates with a potentially lower OHSS risk profile, representing a meaningful advance for high-OHSS-risk patients.
PT-141's relevance to fertility research is indirect but practically acknowledged. Sexual dysfunction — including loss of libido, arousal difficulties, or dyspareunia — can impair natural conception independent of hormonal or anatomical fertility parameters. PT-141 has been FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, addressing a CNS-mediated sexual dysfunction that conventional hormonal treatments may not fully resolve. In fertility research contexts, PT-141 is not considered a direct fertility agent — it does not affect ovulation, gonadotropin levels, sperm parameters, or gamete quality — but its role in restoring sexual motivation and arousal may be relevant in the broader context of reproductive health.
Compound Notes
Kisspeptin
Kisspeptin is the most well-documented peptide in fertility research on this page. Its KISS1R (GPR54) agonism drives GnRH neuron firing in the hypothalamic arcuate and anteroventral periventricular nuclei, and clinical trials have demonstrated its capacity to trigger a physiologically patterned LH surge when administered IV. Published data from Hammersmith Hospital and Imperial College London support its use as an IVF ovulation trigger, with Phase 2 and Phase 3 data showing oocyte retrieval rates comparable to hCG with a potentially reduced OHSS risk. Research has also investigated Kisspeptin for its potential role in male fertility: IV administration has been shown to stimulate LH and testosterone pulsatility in men with congenital hypogonadotropic hypogonadism, and SubQ protocols have been explored for longer-term axis stimulation. Kisspeptin is investigational outside of approved IVF trigger protocols.
PT-141
PT-141 (bremelanotide / Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is not a direct fertility compound. Its mechanism — MC3R/MC4R agonism in the hypothalamus and limbic system — drives CNS-mediated sexual arousal and motivation independently of oestrogen or testosterone levels, which distinguishes it from hormone-based approaches to sexual dysfunction. In a fertility context, PT-141 addresses the psychosexual dimension of reproductive function rather than hormonal or gametic parameters. Reported side effects in research and anecdotal accounts include flushing, nausea, transient blood pressure elevation, and hyperpigmentation with chronic use. It is administered SubQ on an as-needed basis, commonly reported 1–2 hours before anticipated sexual activity.
Commonly Reported Combinations
No established combination protocols exist for the compounds on this page in fertility contexts. Kisspeptin is administered under clinical supervision as a discrete trigger in IVF protocols or as an investigational axis stimulant; it is not commonly reported in off-protocol combination with other peptides. PT-141 is reported independently for arousal and libido.
Researchers and clinicians addressing both hormonal fertility parameters and sexual function may consider these compounds sequentially rather than simultaneously. For hormonal support contexts that extend beyond active fertility treatment, see the Testosterone & Hormonal Support goal page.
Frequently Asked Questions
How is Kisspeptin used as an IVF trigger instead of hCG?
In IVF stimulation protocols, follicles are grown using FSH injections over approximately 10–14 days. When follicles reach target size, a trigger injection is administered to induce final oocyte maturation and prepare for retrieval 34–36 hours later. Conventionally, hCG is used as the trigger because it mimics LH and has a long half-life. Kisspeptin-10 is administered IV as an alternative: it stimulates the pituitary's own LH surge by acting upstream on GnRH neurons, producing a physiologically patterned release that self-terminates as kisspeptin clears from circulation within hours. This avoids the sustained LH-like stimulation from hCG, which is implicated in OHSS pathogenesis.
What is OHSS and why might Kisspeptin reduce its risk?
Ovarian hyperstimulation syndrome (OHSS) is a potentially serious complication of ovarian stimulation in IVF, characterised by ovarian enlargement, abdominal discomfort, fluid accumulation in the abdomen or thorax, and in severe cases, thromboembolism. It is driven by excessive vascular permeability, mediated in part by VEGF released from hyperstimulated ovaries. hCG is particularly associated with late-onset OHSS because its long half-life (several days) sustains the luteal stimulus that drives ovarian VEGF production. A Kisspeptin trigger, by generating a self-terminating endogenous LH surge, removes this sustained stimulus and may reduce the downstream VEGF response. Clinical trial data suggests this translates to a reduced OHSS incidence, particularly in high-risk patients with polycystic ovary syndrome or large antral follicle counts.
Does PT-141 actually improve fertility, or only libido?
PT-141 does not directly affect fertility parameters. It does not alter ovulation timing, gonadotropin levels, sperm parameters, endometrial receptivity, or any other measured reproductive outcome. Its mechanism — CNS melanocortin receptor agonism driving sexual arousal and motivation — is neurological rather than endocrine or reproductive. Research has investigated PT-141 for its potential role in hypoactive sexual desire disorder and sexual dysfunction, outcomes that are distinct from fertility in the biological sense. Its relevance to a fertility page is limited to the practical observation that sexual dysfunction can impair natural conception frequency and that treating this psychosexual component may support fertility indirectly.
What does Kisspeptin research show specifically for male infertility?
Research has investigated Kisspeptin for its potential role in male hypogonadotropic hypogonadism — a condition in which low testosterone and impaired spermatogenesis stem from insufficient hypothalamic GnRH pulsatility rather than primary testicular failure. Published studies at Imperial College London have demonstrated that IV Kisspeptin administration in men with congenital hypogonadotropic hypogonadism restores LH pulsatility and stimulates testosterone secretion. SubQ administration protocols have also been explored for longer-duration axis stimulation. Whether Kisspeptin can restore spermatogenesis sufficiently to achieve natural fertility in these patients — a multi-month process dependent on sustained FSH support — has been less extensively studied than the acute hormonal response, and it remains an active area of clinical investigation.